Safety
pancreatitis
ADVERSE EVENTS, ADVERSE EVENT, PANCREATITIS
Overall, 87.1% of the 287 tirzepatide-treated participants reported at least one treatment-emergent adverse event compared with 76.7% of the 292 placebo-treated participants (Table Serious adverse events were reported by 31 participants (5.4%) overall. Occurrence was similar in participants treated with tirzepatide (5.9%) and placebo (4.8%) (Table Adjudication-confirmed cases of pancreatitis were reported in 0.3% (one) of participants in the tirzepatide MTD group and 0.3% (one) of participants in the placebo group from randomization to safety follow-up (Table 